V8 Peptides — Engineered Performance
Research Library
History of TB-500 and Thymosin β4 Research
TB-500History

History of TB-500 and Thymosin β4 Research

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What is the history of TB-500 peptide research? TB-500 traces back to thymosin β4 (Tβ4), a 43-residue protein first isolated from thymus-derived extracts in the late 1970s and later shown to be the main G-actin-sequestering molecule inside cells. Key milestones are its amino acid sequence (1981), its identification as an actin-binding peptide (1991), cell-migration and wound-model studies (1997–1999) and the 2003–2004 work that located an actin-binding motif, Ac-LKKTETQ (residues 17–23), within the molecule. The TB-500 research vial corresponds to that 17–23 fragment. This is a literature timeline for laboratory readers, with no use claims.

Few research peptides carry as tangled a naming history as TB-500. The label appears in supplier catalogs and forum threads, but the science behind it sits in a thirty-year literature on thymosin β4. This article lays out that literature in order: where the parent protein came from, how its function was worked out, why a short fragment became a research tool, and where the name creates confusion. It complements the TB-500 research overview and the side-by-side TB-500 vs thymosin beta-4 differences by following events in time rather than describing the compound.

Origins: thymus extracts and the thymosin family

The story starts with the thymus rather than with actin. In the 1960s and 1970s, Allan Goldstein and colleagues prepared partially purified calf thymus extracts and fractionated them, naming the active components thymosins. Thymosin fraction 5 was a mixture of many small acidic polypeptides, and individual members were later separated and sequenced. Thymosin α1, a distinct 28-residue peptide from that effort, is its own research subject (see what is thymosin alpha 1); Tβ4 was a different component of the same fractions, named by its behavior on electrophoresis.

The key point for dating TB-500 is that the original rationale was immunological, and the cell-biology identity of Tβ4 emerged later, when other labs found the same peptide in tissues with no thymic connection.

1981 to 1982: sequence and ubiquity

Low, Hu and Goldstein (1981) reported the complete amino acid sequence of bovine thymosin β4: 43 residues, a molecular mass near 4.9 kDa, an acetylated N-terminus and no cysteine. A year later Hannappel and colleagues (1982) measured Tβ4 across rat and mouse tissues and found it to be a ubiquitous peptide, abundant in spleen, thymus and many other organs. That result broke the link to the thymus: a peptide present at high concentration in nearly all nucleated cells was unlikely to be a thymus-specific hormone and more likely to play a cell-intrinsic role. Background on how sequences are written and read is given in understanding amino acid sequences.

1991: an actin-sequestering protein

The function was settled by actin biochemists. Safer, Elzinga and Nachmias (1991) showed that a previously described actin-sequestering peptide called Fx and thymosin β4 were the same molecule. By binding monomeric G-actin in a 1:1 complex, Tβ4 holds a reserve of unpolymerized actin that a cell can draw on when it needs to assemble filaments. That finding turned Tβ4 from an immune-system curiosity into a cytoskeletal regulator and defined most of the later work on cell migration. A review by Goldstein, Hannappel and Kleinman (2005) later summarized how the same molecule was repeatedly found to act outside its actin-binding role.

1997 to 1999: migration and wound models

With a mechanism in hand, laboratories asked what Tβ4 does when it is supplied to cells and tissues. Malinda and colleagues (1997) reported that Tβ4 stimulated directional migration of human umbilical vein endothelial cells in culture. Two years later the same group reported accelerated wound closure in a rat dermal wound model (Malinda et al., 1999), and Grant and colleagues (1999) described effects on endothelial differentiation and in angiogenesis assays. These are the origin of the repeated pairing of thymosin β4 with cell migration and tissue-response models. They are in vitro and animal observations, reported in the specific systems and conditions of those papers, and they do not translate into statements about use outside the laboratory. A more detailed treatment of the migration assays is in the companion TB-500 angiogenesis and cell migration assay guide.

2003 to 2004: a motif and a signaling pathway

Two papers set the stage for fragment research. Philp and colleagues (2003) reported that the actin-binding region of Tβ4, centered on the heptapeptide LKKTETQ, promoted angiogenesis in assays, suggesting that a short sequence retained some of the activity of the parent protein. Bock-Marquette and colleagues (2004) reported in Nature that Tβ4 interacted with integrin-linked kinase and promoted cardiac cell migration and survival in a mouse model, work that drew wide attention to the molecule. Together they established two ideas: that Tβ4 acts through more than one route, and that its activity might be mapped to short regions. The 17–23 sequence, with an acetylated N-terminus (Ac-LKKTETQ), is the fragment the V8 product page defines for TB-500, at about 889 Da with molecular formula C38H68N10O14.

It is worth noting what these two papers did not do. Neither tested the acetylated heptapeptide as a stand-alone reagent across the range of assays later associated with the name, and neither supports conclusions about use outside the laboratory. Reading the original methods sections, rather than secondary summaries, is the reliable way to see which molecule, species and concentration range each result applies to.

Dating matters for a second reason: reagent quality. Early thymosin work relied on tissue-purified protein, and later work moved to recombinant and synthetic material, so purity and identity checks were not uniform across decades. A modern reader comparing figures should therefore note the source of the peptide in each paper.

Where the name TB-500 came from

There is no international nonproprietary name or pharmacopoeial monograph for TB-500, and the label's origin is a matter of catalog usage rather than a formal designation. Different sellers and different papers have used it for full-length Tβ4, for the 17–23 fragment, or for other analogs. That ambiguity is why identity documentation matters. When reading a source, check whether it describes the 43-residue protein or the heptapeptide fragment, because their molecular masses differ by a factor of five and their receptor and actin-binding behavior cannot be assumed to match. The comparison page cited above works through this distinction in detail.

FeatureThymosin β4 (full length)TB-500 as defined on the V8 product page
Length43 amino acids7 amino acids (residues 17–23)
Approximate massAbout 4.9 kDaAbout 889 Da
SequenceAc-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGESAc-LKKTETQ
Actin-binding regionContains it within the 17–23 stretchIs that stretch
Main literature1981 sequence, 1991 actin work, 1997–2004 cell and tissue modelsDerived from the 2003 mapping of the actin-binding motif

A timeline of the main milestones

YearMilestoneWhy it matters
1960s–1970sThymosin fractions prepared from calf thymusSource of the original peptide family
1981Bovine Tβ4 sequencedGave the 43-residue reference structure
1982Tβ4 found in many tissuesShowed it is cell-intrinsic, not thymus-specific
1991Tβ4 identified as an actin-sequestering peptideEstablished the central mechanism
1997–1999Endothelial migration and rat wound studiesOrigin of the migration and tissue-response research angle
2003–2004LKKTETQ motif mapped; integrin-linked kinase paperLed to short-fragment research tools

How the history shapes laboratory practice today

Three practical lessons follow. First, define the molecule in every notebook entry: full-length Tβ4 and the 17–23 fragment are not interchangeable, and a figure from one paper should not be pinned to the other without evidence. Second, interpret older migration and wound data as system-specific: the endothelial cells, rat wound geometry and reagent sources of the 1990s differ from modern assay conditions. Third, check material identity independently. The TB-500 purity testing page explains how HPLC and mass data are read, and a certificate, where published, is listed in the COA library. For a short, hydrophilic acetylated peptide, the concentration arithmetic in the calculator is straightforward, but mass should be corrected for net peptide content when the experiment needs exact molarity.

If you are comparing TB-500 with other tissue-response research peptides, BPC-157 vs TB-500 sets out how the two literatures differ, and where to buy TB-500 lists the documentation to look for when sourcing research material.

All material discussed here is supplied for laboratory research use only; not for human consumption, not a drug, food or cosmetic.

Related reading

Frequently asked questions

What is TB-500 in the research literature?

The V8 product page defines it as a synthetic 17–23 fragment of thymosin β4, Ac-LKKTETQ, about 889 Da. Other sources use the label for full-length thymosin β4 or other analogs, so always check the sequence.

Where did thymosin β4 come from?

It was found in the fractionated calf thymus extracts prepared by Goldstein and colleagues, and its sequence was reported in 1981. It was later found in nearly all nucleated cells, not only the thymus.

How long is thymosin β4?

The full-length protein has 43 amino acids and a mass close to 4.9 kDa, with an acetylated N-terminus and no cysteine residues.

What is the main cellular role of thymosin β4?

It binds monomeric G-actin and keeps a pool of unpolymerized actin available, which is why it is studied in cytoskeletal regulation and cell migration.

Who showed that Fx and thymosin β4 are the same?

Safer, Elzinga and Nachmias reported in 1991 that the actin-sequestering peptide Fx was indistinguishable from thymosin β4.

Why is LKKTETQ important?

Philp and colleagues reported in 2003 that this actin-binding region promoted angiogenesis in assays, which supported research on short fragments as tools.

Is there an official name or monograph for TB-500?

No international nonproprietary name or pharmacopoeial monograph exists for the label, which is why catalog definitions vary between sources.

Do the older wound and migration studies apply to the fragment?

Not automatically. Most early studies used full-length thymosin β4 in specific cells and animal models. Results should not be assumed to transfer to the fragment.

Does V8 publish a certificate for TB-500?

Certificates are listed in the COA library where published. The product page lists a specification of ≥98% purity by HPLC and a 10 mg lyophilized vial for laboratory research use only.

How should TB-500 be stored?

The product page states refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.

Related reading: TB-500: Angiogenesis and Cell Migration Assay Guide, TB-500 Laboratory Safety and Handling Guide.

Related reading: Wolverine Stack Research Design: BPC-157 + TB-500 Ratios.

References

  1. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA. 1981;78(2):1162-1166. doi:10.1073/pnas.78.2.1162
  2. Hannappel E, Xu GJ, Morgan J, Hempstead J, Horecker BL. Thymosin β4: a ubiquitous peptide in rat and mouse tissues. Proc Natl Acad Sci USA. 1982;79(7):2172-2175. doi:10.1073/pnas.79.7.2172
  3. Safer D, Elzinga M, Nachmias VT. Thymosin β4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. doi:10.1016/S0021-9258(20)64278-8
  4. Malinda KM, Goldstein AL, Kleinman HK. Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. doi:10.1096/fasebj.11.6.9194528
  5. Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
  6. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. doi:10.1096/fj.03-0121fje
  7. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
  8. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.